The firm will provide manufacturing and regulatory support as UW prepares an IND submission for its GD2 CAR T-cell therapy.

The nonprofit Finding Hope for Frizzle aims to initiate a clinical trial of the gene therapy for FRRS1L disease in the second half of 2026.

A study evaluated agreement between 10 AI digital pathology tools in assessing IHC-based HER2 expression and found the most variability in identifying HER2-low samples.

The driving force behind the lab was a desire to control biomarker discovery, streamline regulatory approvals for CDx, and develop drugs more cheaply and quickly.

The gene therapy, which was acquired by Novartis in 2023, is also being tested in a separate Phase I/II trial of pediatric ...

The firm said a Phase III trial, comparing adjuvant Retevmo against placebo, met its primary endpoint of event-free survival.

Givastomig is being developed for HER2-negative first-line gastric cancer that expresses CLDN18.2 in combination with Bristol Myers Squibb's checkpoint inhibitor Opdivo (nivolumab) and FOLFOX ...

The drugmaker terminated the first-in-human Phase I/II trial after a year, determining that the clinical data did not support further investigation.

Distance, lack of coverage, and mistrust have limited Indigenous patients' access to basic and advanced medicine, but cancer centers are embracing strategies to change that.

Researchers evaluated a different chemo regimen in combination with Braftovi and Erbitux, which is already approved with mFOLFOX6.

The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.

The company acquired GH31 from Chinese firm Genhouse for $80 million up front and will test it in tumors with MTAP deletions.